[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cradiovascular-kidney-liver-metabolic-cklm-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cradiovascular-kidney-liver-metabolic-cklm-syndrome":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100599453","swiss-cardiovascular-kidney-liver-metabolic-cklm-registry-100599453",false,"NCT07084688","Swiss Cardiovascular-Kidney-Liver-Metabolic (CKLM) Registry","Inclusion Criteria:\n\n* At least 18 years of age\n* Individuals diagnosed with cardiovascular-kidney-metabolic (CKM) syndrome stages 0 to 3 according to the American Heart Association (AHA) or liver disease defined by any of the following:\n\n  * For stage 0: Individuals without overweight\u002Fobesity, metabolic risk factors (normoglycemia, normotension, normal lipid profile), Chronic kidney disease (CKD), or Cardiovascular disease (CVD)\n  * Individuals with overweight\u002Fobesity or dysfunctional adipose tissue, without other metabolic risk factors or CKD\n  * Individuals with metabolic risk factors (hypertriglyceridemia, arterial hypertension, metabolic syndrome, diabetes) or CKD\n  * Subclinical Atherosclerotic cardiovascular disease (ASCVD) or subclinical heart failure (HF) in individuals with excess\u002Fdysfunctional adiposity, other metabolic risk factors, or CKD in the clinical assessment\\[2\\]\n  * Independent of CKM syndrome stages, individual with signs of hepatic steatosis on imaging\n* Willingness to provide informed consent\n\nExclusion Criteria:\n\n* Individuals with CKM syndrome stage 4 according to the AHA\n\n  \\* Individuals with clinical cardiovascular disease including:\n  * History of coronary artery disease, myocardial infarction, coronary artery intervention\n  * History of atrial fibrillation\n  * History of stroke\n  * Symptomatic peripheral artery disease (\\>stage I)\n  * History of symptomatic HF\n  * History of HF hospitalisation\n* Inability to sign informed consent",true,"ALL","18 Years",{"count":19,"type":20},1500,"ESTIMATED","10 Years","OBSERVATIONAL","The aim of this clinical and exploratory Swiss Cardiovascular-Kidney-Liver-Metabolic (CKLM) Registry is to establish high quality prevalence and incidence database for Cardiovascular-Kidney-Metabolic (CKM) syndrome, its major contributors, and the extent of the respective organ damaged.",[25,26],"Cradiovascular-kidney-liver-metabolic (CKLM) Syndrome","Cardiovascular-kidney-metabolic Syndrome",[28,29,30,31,32],"Cardiovascular-kidney-liver-metabolic (CKLM) syndrome","Cardiovascular disease (CVD)","Chronic kidney disease (CKD)","Organ-specific diseases","Cardiovascular-kidney-metabolic (CKM) syndrome","NOT_YET_RECRUITING","2025-07-17",{"date":36,"type":37},"2025-07-24","ACTUAL",{"date":39,"type":20},"2025-07-14",{"date":41,"type":20},"2040-07",{"name":43,"class":44},"University Hospital, Basel, Switzerland","OTHER"]